As the spread of the influenza A (H1N1) virus shows no signs of slowing down, researchers worldwide are expediting efforts to develop a vaccine to contain the fatal disease. The World Health Organization (WHO) reported that since the outbreak, nearly 10,000 people in over 40 countries have suffered from the virus, claiming 79 lives.
Manufacturing the new vaccine has become significant because experts have found that the regular flu vaccine does not render immunity against the new flu. There are setbacks, however. Health officials who attended WHO’s annual meeting are doubtful about the possibility of developing a vaccine sooner because of difficulty in producing lab-grown swine flu virus, which is the source of “seed stock” needed to develop a new vaccine. They estimate that production will take approximately four to six months, starting at the end of May 2009.
Researchers in South Korea hope to ease this difficulty however, reporting that they have managed to develop a genetically modified version of a live virus that will lead to the development of a new vaccine against H1N1.
According to Professor Seo Sang-heui of the Chungnam National University’s College of Veterinary Medicine, although what they developed is a “candidate strain” that has to undergo additional testing, he is optimistic that it will lead to positive results. The university has already sent eight vials of the candidate strain to the US Center for Disease and Control (CDCC) for testing.
Britain has also reported some progress in producing a European prototype of the H1N1 vaccine. Its Health Protection Agency has successfully undergone sequencing of the virus’ genetic code – a crucial step in understanding the nature and characteristics of the virus prior to vaccine development.
At present, the H1N1 threat level remains “imminent” at phase five. Debates rage on whether or not to elevate the threat to the highest pandemic level six. Several governments are weary of the unnecessary global panic and confusion this might cause, saying the virus has not turned out as fatal as feared.